

Reference:	FOI.5319.21
Subject:	Lung cancer treatments
Date of Request:	10 February 2021

Requested:

1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

- Atezolizumab
- Carboplatin with Gemcitabine
- Carboplatin with Paclitaxel
- Carboplatin single or in any other combination
- Cisplatin with Gemcitabine
- Cisplatin single or in any other combination
- Nivolumab
- MVAC with G-CSF
- Pembrolizumab
- Any other regimen including Paclitaxel
- Any other chemo regimen
- Other active systemic anti-cancer therapy [please state]
- Palliative care only

2. Could you please provide the total number of patients with any treatment in the last three months for:

- Total non-small cell lung cancer (NSCLC)
- BRAF+ non-small cell lung cancer (NSCLC)

3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib
- Alectinib
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
- Atezolizumab monotherapy
- Bevacizumab
- Brigatinib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel
- Durvalumab
- Erlotinib
- Gefitinib
- Gemcitabine
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib

- Paclitaxel
- Pembrolizumab chemo in combination
- Pembrolizumab monotherapy
- Pemetrexed with Carboplatin
- Pemetrexed with Cisplatin
- Vinorelbine and cisplatin/carboplatin

Response:

This information is already within the public domain; therefore, Hywel Dda University Health Board (UHB) has applied an Exemption under Section 21 of the Freedom of Information Act 2000 (the Act), as the information is accessible by another means. The UHB has answered a similar Freedom of Information request, FOI/4171/20, which is available on our disclosure log.

For ease of reference please click on the attached link which will take you directly to the UHB's disclosure log webpage:

<https://hduhb.nhs.wales/about-us/governance-arrangements/freedom-of-information/disclosure-log/>